CELC Latest Headlines

Celcuity's $500M Convertible Notes Offering Signals Strategic Push for Growth and R&D Advancements

Market Chameleon (Thu, 4-Jun 9:08 AM)

Celcuity’s Positive Phase 3 Results and Expanding Trials Highlight Ambitious Path for Gedatolisib

Market Chameleon (Fri, 15-May 11:14 AM)

Celcuity’s Phase 3 VIKTORIA-1 Results Highlight Promising New Pathway for Advanced Breast Cancer Patients with PIK3CA Mutations

Market Chameleon (Mon, 4-May 10:31 AM)

Celcuity’s VIKTORIA-1 Trial Marks Major Advance in PIK3CA Mutant Breast Cancer Treatment

Market Chameleon (Mon, 4-May 7:06 AM)